{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:10:19Z","timestamp":1784193019308,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.antiviral.2012.05.004","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T18:04:50Z","timestamp":1337709890000},"page":"172-181","source":"Crossref","is-referenced-by-count":11,"title":["Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice"],"prefix":"10.1016","volume":"95","author":[{"given":"Lora","family":"Simeonova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Gegova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel S.","family":"Galabov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2012.05.004_b0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/135965350701200S04.1","article-title":"Influenza virus susceptibility and resistance to oseltamivir","volume":"12","author":"Aoki","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2012.05.004_b0010","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.antiviral.2010.09.020","article-title":"Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model","volume":"88","author":"Bantia","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.05.004_b0015","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1128\/JVI.62.5.1508-1512.1988","article-title":"Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection","volume":"62","author":"Belshe","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.05.004_b0020","unstructured":"CDC, 2008. CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1). viruses, 2008-09 influenza season. Available at: http:\/\/emergency.cdc.gov\/HAN\/han00279.asp."},{"key":"10.1016\/j.antiviral.2012.05.004_b0025","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3201\/eid1512.091057","article-title":"Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong","volume":"15","author":"Chen","year":"2009","journal-title":"China. Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.05.004_b0030","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1506.081357","article-title":"Oseltamivir- and amantadine-resistant influenza viruses A (H1N1)","volume":"15","author":"Cheng","year":"2009","journal-title":"Emerg. Infect Dis."},{"key":"10.1016\/j.antiviral.2012.05.004_b0035","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMoa0903810","article-title":"Emergence of a novel swine-origin influenza A (H1N1) virus in humans","volume":"360","author":"Dawood","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.05.004_b0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1086\/518936","article-title":"Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide","volume":"196","author":"Deyde","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.05.004_b0045","doi-asserted-by":"crossref","unstructured":"Galabov, A.S., Uzunov, S., Tancheva, L., Velichkova E., Hadjiathanassova V., 1991. An effective anti-influenza virus combination of mopyridone and rimantadine hydrochloride. Antiviral Res. 15 (Suppl. I) (Forth Intern. Conference on Antiviral Res., New Orleans, Louisiana, 21\u201326.04.1991, 141.","DOI":"10.1016\/0166-3542(91)90269-W"},{"key":"10.1016\/j.antiviral.2012.05.004_b0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/095632020601700502","article-title":"Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice","volume":"17","author":"Galabov","year":"2006","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0055","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3390\/v2081510","article-title":"Combination chemotherapy for influenza.","volume":"2","author":"Govorkova","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2012.05.004_b0060","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1128\/AAC.48.12.4855-4863.2004","article-title":"Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effect in MDCK cells","volume":"48","author":"Govorkova","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0065","doi-asserted-by":"crossref","unstructured":"Harvala, H., Gunson, R., Simmonds, P., Hardie, A., Bennett, S., Scott, F., Roddie, H., McKnight, J., Walsh, T., Rowney, D., Clark, A., Bremner, J., Aitken, C., Templeton, K., 2010. The emergence of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009. Euro Surveill. 15, pii: 19536.","DOI":"10.2807\/ese.15.14.19536-en"},{"key":"10.1016\/j.antiviral.2012.05.004_b0070","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/j.1460-2075.1985.tb04038.x","article-title":"The molecular basis of the specific anti-influenza action of amantadine","volume":"4","author":"Hay","year":"1985","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2012.05.004_b0075","doi-asserted-by":"crossref","unstructured":"Hay, A.J., Zambon, M.C., Wolstenholme, A.J., Shekel, J.J., Smith, M.H., 1986. Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrob. Chemother. 18 (Suppl. B), 19\u201329.","DOI":"10.1093\/jac\/18.Supplement_B.19"},{"key":"10.1016\/j.antiviral.2012.05.004_b0080","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrmicro1208","article-title":"Influenza: lessons from past pandemics, warnings from current incidents","volume":"3","author":"Horimoto","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2012.05.004_b0085","doi-asserted-by":"crossref","unstructured":"Hurt, A.C., Lee, R.T., Leang, S.K., Cui, L., Deng, Y.M., Phuah, S.P., Caldwell, N., Freeman, K., Komadina, N., Smith, D., Speers, D., Kelso, A., Lin, R.T., Maurer-Stroh, S., Barr, I.G., 2011. Increased detection in Australia and Singapore of a novel influenza A(H1N1) variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill. 16, pii: 19884.","DOI":"10.2807\/ese.16.23.19884-en"},{"key":"10.1016\/j.antiviral.2012.05.004_b0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2006.01.012","article-title":"Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants","volume":"70","author":"Ilyushina","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.05.004_b0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/135965350701200302","article-title":"Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice","volume":"12","author":"Ilyushina","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2012.05.004_b0100","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1128\/AAC.01579-07","article-title":"Oseltamivir\u2013ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice","volume":"52","author":"Ilyushina","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0105","unstructured":"Kable, S., 2009. Proposal for the inclusion of amantadine and rimantadine in the World Health Organization model list of essential medicines. 17th Expert Committee on the Selection and Use of Essential Medicines, Geneva, March 2009, pp. 1\u201342."},{"key":"10.1016\/j.antiviral.2012.05.004_b0110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2012.05.004_b0115","doi-asserted-by":"crossref","unstructured":"Lackenby, A., Hungnes, O., Dudman, S.G., Meijer, A., Paget, W.J., Hay, A.J. et al., 2008. Emergence of resistance to oseltamivir among infl uenza A(H1N1) viruses in Europe. Euro Surveill. 13, pii: 8026.","DOI":"10.2807\/ese.13.05.08026-en"},{"key":"10.1016\/j.antiviral.2012.05.004_b0120","doi-asserted-by":"crossref","unstructured":"Lackenby, A., Moran Gilad, J., Pebody, R., Miah, S., Calatayud, L., Bolotin, S., Vipond, I., Muir P., Guiver, M., McMenamin, J., Reynolds, A., Moore, C., Gunson, R., Thompson, C., Galiano, M., Bermingham, A., Ellis, J., Zambon, M., 2011. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010\/11. Euro Surveill.16, pii: 19784.","DOI":"10.2807\/ese.16.05.19784-en"},{"key":"10.1016\/j.antiviral.2012.05.004_b0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(00)00123-6","article-title":"The neuraminidase inhibitor GS 4104 (oseltamivir phosphate) is efficacious against A\/Hong Kong\/156\/97 (H5N1) and A\/Hong Kong\/1074\/99 (H9N2) influenza virus","volume":"48","author":"Leneva","year":"2000","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.05.004_b0130","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1179\/joc.2007.19.3.295","article-title":"Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infection in mice","volume":"19","author":"Masihi","year":"2007","journal-title":"J. Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0135","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1128\/AAC.47.7.2264-2272.2003","article-title":"Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir","volume":"47","author":"McKimm-Breschkin","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0140","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1128\/AAC.01339-05","article-title":"Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use","volume":"50","author":"Monto","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0145","doi-asserted-by":"crossref","first-page":"e1305","DOI":"10.1371\/journal.pone.0001305","article-title":"A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination","volume":"2","author":"Morrison","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2012.05.004_b0150","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.05.004_b0155","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1056\/NEJMp058291","article-title":"Oseltamivir resistance \u2013 disabling our influenza defenses","volume":"353","author":"Moscona","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.05.004_b0160","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.virol.2009.03.026","article-title":"The origin and global emergence of adamantane resistant A\/H3N2 influenza viruses","volume":"388","author":"Nelson","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2012.05.004_b0165","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1128\/AAC.00476-09","article-title":"Triple combination of oseltamivir, amantadine, and ribavirin is highly synergistic against multiple strains of influenza A","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0170","doi-asserted-by":"crossref","first-page":"e9332","DOI":"10.1371\/journal.pone.0009332","article-title":"Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro","volume":"5","author":"Nguyen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2012.05.004_b0175","doi-asserted-by":"crossref","first-page":"e31006","DOI":"10.1371\/journal.pone.0031006","article-title":"Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses","volume":"7","author":"Nguyen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2012.05.004_b0180","first-page":"73","article-title":"Antiviral effect of combination of enviroxim and disoxaril on Coxsackievirus B1 infection","volume":"44","author":"Nikolaeva","year":"2000","journal-title":"Acta Virol."},{"key":"10.1016\/j.antiviral.2012.05.004_b0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimentional model to analyze drug\u2013drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.05.004_b0190","series-title":"User\u2019s Manual","author":"Prichard","year":"1992"},{"key":"10.1016\/j.antiviral.2012.05.004_b0195","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.antiviral.2011.04.003","article-title":"Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004\/05 to 2009\/10 epidemics and from the recent 2009 pandemic","volume":"90","author":"Puzelli","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.05.004_b0200","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.00555-08","article-title":"Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide in 2004\u20132008","volume":"52","author":"Sheu","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0205","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1128\/AEM.16.2.370-392.1968","article-title":"In vivo antiviral properties of biologically active compounds. II. studies with influenza and vaccinia viruses","volume":"16","author":"Sidwell","year":"1968","journal-title":"Appl. Microbiol."},{"key":"10.1016\/j.antiviral.2012.05.004_b0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-3542(97)00065-X","article-title":"Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor","volume":"14","author":"Sidwell","year":"1998","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.05.004_b0215","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice","volume":"54","author":"Smee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0220","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/AAC.01012-08","article-title":"Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice","volume":"53","author":"Smee","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.05.004_b0225","unstructured":"World Health Organization, 2006. Update on avian influenza, Turkey. Wkly. Epidemiol. Rec. 81, 22\u201334. Available at: http:\/\/www.who.int\/wer\/2006\/wer8103.pdf."},{"key":"10.1016\/j.antiviral.2012.05.004_b0230","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jcv.2011.04.001","article-title":"Genetic diversity and antiviral drug resistance of pandemic H1N1 2009 in Lebanon","volume":"51","author":"Zaraket","year":"2011","journal-title":"J. Clin. Vir."},{"key":"10.1016\/j.antiviral.2012.05.004_b0235","unstructured":"http:\/\/www.timesonline.co.uk\/tol\/news\/world\/asia\/article1549260."},{"key":"10.1016\/j.antiviral.2012.05.004_b0240","unstructured":"http:\/\/www.medscape.com\/viewarticle\/547783."},{"key":"10.1016\/j.antiviral.2012.05.004_b0245","unstructured":"www.who.int\/csr\/disease\/swineflu\/notes\/h1n1_antiviral_resistance_20090708\/en\/index.html."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421200109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421200109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T21:58:35Z","timestamp":1687471115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421200109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S016635421200109X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.05.004","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}